The USC Norris Comprehensive Cancer Center (NCCC) is requesting $450,000 per year in Developmental Funds to be used for new investigator support to recruit faculty level scientists in areas of strategic need and to fund innovative pilot projects. These funds will be crucial to our success as we continue to expand the number of investigators supported by the NCCC to fill the newly constructed research space in the Harlyne Norris Research Tower (HNRT). The HNRT is approximately 70% occupied and still has space for an additional 15 investigators. All recruitments are strategic to the NCCC's goals and have been discussed at our leadership retreats, approved by our Cancer Center Leadership Council and Cancer Center Executive Committee and evaluated by our External Advisory Committee. We will allocate our new investigator support annually at the recommendation of the Cancer Center Director and with the advice of our External Advisory Committee and the approval of the Executive Committee. Pilot project funds will be allocated after the review and recommendation for funding by the Leadership Council through the Whittier Initiative. Developmental Funds awarded during the past five years were allocated primarily to the recruitment of new investigators. The remaining portion was used to fund innovative pilot projects and to establish new shared resources

Public Health Relevance

Developmental Funds allow the NCCC to fund innovative pilot projects and hire additional investigators to perform translational research for the development of more effective prevention, diagnosis, treatment of cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Southern California
Los Angeles
United States
Zip Code
Lawrenson, Kate; Grun, Barbara; Lee, Nathan et al. (2015) NPPB is a novel candidate biomarker expressed by cancer-associated fibroblasts in epithelial ovarian cancer. Int J Cancer 136:1390-401
Milam, Joel E; Meeske, Kathleen; Slaughter, Rhona I et al. (2015) Cancer-related follow-up care among Hispanic and non-Hispanic childhood cancer survivors: The Project Forward study. Cancer 121:605-13
Maus, M K H; Hanna, D L; Stephens, C L et al. (2015) Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics J 15:354-62
Hirsch, Louis; Nazari, Hossein; Sreekumar, Parameswaran G et al. (2015) TGF-?2 secretion from RPE decreases with polarization and becomes apically oriented. Cytokine 71:394-6
Chuh, Kelly N; Pratt, Matthew R (2015) Chemical methods for the proteome-wide identification of posttranslationally modified proteins. Curr Opin Chem Biol 24:27-37
Zhang, Hongjun; Boddupally, Keerthi; Kandyba, Eve et al. (2014) Defining the localization and molecular characteristic of minor salivary gland label-retaining cells. Stem Cells 32:2267-77
Wu, Dai-Ying; Ou, Chen-Yin; Chodankar, Rajas et al. (2014) Distinct, genome-wide, gene-specific selectivity patterns of four glucocorticoid receptor coregulators. Nucl Recept Signal 12:e002
Su, Sheng-Fang; de Castro Abreu, André Luís; Chihara, Yoshitomo et al. (2014) A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res 20:1978-89
Tai, Kenneth P; Le, Valerie V; Selsted, Michael E et al. (2014) Hydrophobic determinants of ?-defensin bactericidal activity. Infect Immun 82:2195-202
Ng, Yuen-Keng; Lee, Jia-Ying; Supko, Kathryn M et al. (2014) Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res 24:207-18

Showing the most recent 10 out of 345 publications